Pod Insights Masters of Scale Extraordinary leaps need solid foundations, part 2, w/Moderna CEO Stéphane Bancel About this episode A diverse network of collaborators is key when making scale leaps. Moderna CEO Stéphane Bancel has cultivated a wide network of scientists, business leaders, and government officials across his career. When COVID-19 struck, Bancel called upon this nexus of experts to aid the warp-speed development of the mRNA-based vaccine in the race to save millions of lives.
Read a transcript of this episode: https://mastersofscale.com https://mastersofscale.com/
Subscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribe
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Transcript 0:01 Speaker 00 We've all spent money on something that seemed incredible, but didn't live up to the hype. A kitchen gadget, a car. When it doesn't deliver, the disappointment is real. Marketers suffer from this too. Chasing metrics that look great, but don't translate into revenue. LinkedIn calls that bull spend. Invest in what matters and reach the right buyers with LinkedIn Ads. You can target by company, industry, job title, and more. LinkedIn Ads also generates the highest ROAS of all major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/Scale. That's LinkedIn.com/Scale. Terms and conditions apply.
0:48 Speaker 00 The very best founders I know are brilliant at building systems. They connect teams, they remove bottlenecks, and they eliminate single points of failure. And yet, when it comes to their own wealth, most are running a disconnected stack. A tax accountant here and a state attorney there, a wealth manager who doesn't talk to either one of them. Creative Planning was built to fix exactly that. One integrated team of tax professionals, state planners, investment specialists, all coordinated by a dedicated wealth manager who sees your full financial picture and keeps every piece working together. Proactive tax efficiency, estate strategy, investments, all under one roof.
1:32 Speaker 00 Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
1:41 Speaker 01 AI is full of possibilities. Enterprises run on realities. That's why Pega combines the world's most powerful AI with the governance, transparency, and control enterprises demand. So you can move faster, adapt faster, and scale AI with confidence. All the power of AI, none of the uncertainty. Learn more at Pega.com/AI.
2:14 Speaker 02 I'm in the south of France with my family.
2:19 Speaker 02 And as every morning of my life, I get up, I go foreign, I come back, I turn on my iPad, and I read the Wall Street Journal.
2:31 Speaker 02 And there's a one page on the iPad article
2:37 Speaker 02 that there is a new virus or bacteria causing pneumonia-like symptoms in Wuhan.
2:47 Speaker 03 That's Stephane Bancel, CEO of Moderna, recalling the January morning in 2020 when he first learned of a mysterious illness in Wuhan, China. For most people, the news out of Wuhan got lost in the holiday season wind down. But for Stephane, who had spent the past decade working with some of the world's leading experts in epidemics, it set alarm bells ringing. He immediately tapped into his global network of scientists to get their take. He sent his first email to Barney Graham, a virologist, working with Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases at the time.
3:23 Speaker 02 I email, I say, "Hey Barney, what's that bug in China?" And when he wakes up because of time difference, he sent me an email, he's like, "Yeah, we just thought about it. We don't know yet. I'll keep you informed."
3:39 Speaker 03 Barney was one of the many scientists in Stephane's planet-spanning network. And as each awoke to the story, the network lit up with information, speculation, and theories.
3:50 Speaker 02 A few days after, we learn it's a virus, which is an important piece for our story because we had done vaccine on viruses before. We've done nine in clinical trials.
4:01 Speaker 03 Having begun nine clinical trials in the past four years, Moderna was particularly well-placed to leap into action against a new virus. By now, Stephane was thinking of little else than the Wuhan virus. And then word came through his network that pathogen had been identified.
4:20 Speaker 02 It's a coronavirus. It's a new one that we've never seen before. And that in a few days, the Chinese are going to put the sequence online.
4:31 Speaker 03 In early January 2020, the Chinese scientists published the genetic sequence of the novel coronavirus, now designated COVID-19. Stephane and his team immediately set to work.
4:43 Speaker 02 The Chinese put the sequence online. Our team designed a vaccine. The time they took between they designed the vaccine and they click order on our software system actually took them 10 minutes.
4:55 Speaker 03 That's right, 10 minutes to design a vaccine for a totally new viral strain using unproven technology. That sequence provided by the scientists in China was like the fingerprint of the new virus. And with it, Bancel and his team could build an mRNA molecule that could help the human immune system identify and kill it.
5:17 Speaker 02 They literally went online. They take their mouse, they copy and paste the instruction set of the spike protein. On the pull down menus, choose 10 or 15 scientific parameters of vaccine and they're done. And of course, we never had access to a physical virus like all traditional pharma. It was just information. So there's a lot of heroes in that. This is a team sport and there are a lot of amazing people that have been part of making this vaccine possible.
5:48 Speaker 03 A process that would normally take months took Stephane's team less time than it does to update your laptop's operating system, although Stephane insisted on taking a couple more days to quadruple check their design. This blistering speed was only possible because Stephane had spent the past decade honing this revolutionary mRNA technology and the platform for producing vaccines. But it also relied on something else, the formidable network of scientists, business leaders, government officials and experts that Stephane had cultivated for his entire career. And Stephane would need to lean into this network many more times over the next six months in the rush to save lives. And that's why I believe you need to prepare
6:32 Speaker 03 to make extraordinary leaps in extraordinary times. And to do this, you need a diverse network of collaborators who share your mission.
6:47 Speaker 04 Fire is burning when you're going home. Can you believe it? Such an idiot. And then you go back to, this is totally gonna be amazing. There are so many easy wins. I have no idea what to do. Sorry, we made a mistake.
6:58 Speaker 05 But you have to time it right.
7:00 Speaker 04 Oops.
7:01 Speaker 05 Working out of a three bedroom apartment.
7:02 Speaker 06 Stuff that just seems absolutely nutballs. 10 years later, we're like, well, that's just how you do it. We haven't made it. Just how you do it.
7:12 Speaker 03 This is Masters of Scale.
7:19 Speaker 03 I'm Reid Hoffman, co-founder of LinkedIn, partner at Greylock, and your host. And I believe you need to prepare to make extraordinary leaps in extraordinary times. And to do this, you need a diverse network of collaborators who share your mission. This is the second episode with Stephane Bancel, CEO of Moderna. In part one, we heard how Stephane cultivated a new risk mindset at Moderna, which enabled the company to build out a platform for launching into action when the world needed it. If you haven't heard it yet, you might want to give it a listen before continuing with this episode. You can find it in the podcast feed. Where we left the story last time, Moderna had made huge strides in developing its mRNA tech and platform.
8:02 Speaker 03 But it had also had a volatile IPO with its share price dropping amid skepticism about its mRNA-based drugs and vaccines, and it hadn't yet released a single product to market. This is when the network that Stephane had built up would prove instrumental to Moderna's survival and its pioneering, lifesaving technology. As we heard Stephane say at the top of this episode, his team was able to design a vaccine in just minutes. However, the full scale of the crisis hadn't emerged. It still seemed then like an isolated outbreak, something that could be easily contained and would peter out rather than becoming a full-scale pandemic.
8:40 Speaker 02 In the early days, we thought, and I thought, that this was going to be an outbreak like SARS and MERS. You know, you're going to have thousands of people, maybe tens of thousands of people infected. Some, of course, will be hospitalized and die, unfortunately. But until the week of January 20, when I was at the World Economic Forum in Davos, I really thought it was an outbreak.
9:01 Speaker 03 At Davos, Stefan kept tracking the numbers. He also met with part of his network in person, namely Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations, and Sir Jeremy Farrar, Director of the UK Research Foundation The Wellcome Trust. Richard and Sir Jeremy were just as concerned about the outbreak in Wuhan as Stefan was.
9:22 Speaker 02 And so they are both infectious disease doc, which I am not. And we talk to each other three, four times a day. Between those sessions, we'll have a coffee together, whatever. And we also get a lot of anecdotes from doctors they know in China that send them email and text them and send them data that's not public yet and so on. And then on Wednesday, the Chinese closed Wuhan.
9:47 Speaker 03 The alarm bells that had been ringing in Stefan's head suddenly became deafening.
9:53 Speaker 02 The first thing that comes to my mind is what do the Chinese know that we don't know? Because I don't remember, until maybe the Middle Ages, a city being closed down. And not even a city of millions of people being closed down like that.
10:12 Speaker 03 Then Stefan had another chilling thought.
10:16 Speaker 02 And the flights coming out of Wuhan, and there are direct flights to every capital in Asia, every capital in Europe, and all the big cities in the US and the West Coast. And I remember looking at that on the iPad and looking back up to Jeremy. I say, "Oh, shit, it is everywhere." And he's like, "Yes, it's everywhere." And I'm like, "We're spreading like crazy." And that's the death we're starting to see in China. It's really bad. He's like, "Yes, it's really bad." I was like, "As bad like the 1918 pandemic?" He's like, "Yeah, it's going to be as bad as 1918 pandemic."
10:52 Speaker 03 That's the 1918 influenza pandemic estimated to have killed as many as 50 million people across the globe. But very few people saw the danger that Stephane, Jeremy and Richard saw, including Stephane's own team.
11:07 Speaker 02 I called my team in Boston and like, it's going to be a pandemic. And they already think I'm crazy. Like, they already, okay, he's totally lost it, he's in Europe, he's having too much wine at the dinner at the house or whatever, which of course was not true. He's like, he's going really off rails, he's crazy.
11:22 Speaker 03 The disbelief from Stephane's team may seem astonishing, but remember, Stephane was plugged directly into a worldwide network of scientists and experts, and he was getting their information and insights in real time. Another expert who realized the gravity of the situation early on was Dr. Charity Dean, Assistant Director of California's Department of Health. In January 2020, she was already convinced that the outbreak in Wuhan had the makings of a pandemic.
11:49 Speaker 07 So by the second and third week of January, I was incredibly alarmed. I was 90% sure this was absolutely a novel pathogen and this was going to be a global pandemic. What I did, what every good disease controller does, is they check their thinking with their colleagues and their trusted networks. For me, that was very sharp trusted local health officers who had been my colleagues for 10 years. I knew their judgment, I knew what they worried about, I knew they weren't chicken littles. The other network that I tapped into quickly was my network of physicians. You know, every physician that does communicable disease has a trusted network of infectious disease doctors and epidemiologists and internal medicine physicians, pulmonologists, ER docs.
12:34 Speaker 03 Through that network of physicians, Charity learned when doctors in California started seeing instances of a new pneumonia-like illness. She used the information she gathered to map out the possible scale of the pandemic in California and projected a shocking 20 million cases by May. Charity and her team struggled to make the wider authorities take the outbreak seriously. But then, in February, she tapped into a new network known as the Wolverines, a group of seven doctors who had previously worked in the White House. They shared Charity's alarm and a sense of intense urgency.
13:09 Speaker 07 The Wolverine sharpened my thinking in a number of ways, certainly being empowered to take the actions that I knew California needed to take. And it required sticking my neck out.
13:20 Speaker 03 One of those bold actions was changing the state's guidelines for COVID testing ahead of the rest of the nation.
13:27 Speaker 07 The CDC's testing guidance basically prohibited someone from being tested if they hadn't returned from Wuhan or China, or they weren't in the ICU. And I was leading the California testing task force, and it was so clear to me the testing guidance needed to be changed. But most states didn't want to lean forward and do something before the CDC did. But at that point, I said, we're Califor-ic-n-fornia. Of course, we should be leading the country. We know the right thing to do.
13:55 Speaker 03 Charity updated the guidance so far more people could be tested for COVID.
13:59 Speaker 07 That's when it kind of blew the roof off the data. And we realized COVID is very widespread in communities. And if we hadn't changed that testing guidance, we wouldn't know. So there were 1,000 brave moments like that. Not just me, every public servant was taking. And we did it because we collectively had each other. And we were cheering for each other, and we were talking to each other behind the scenes.
14:24 Speaker 03 Charity's network of collaborators helped to realize the shocking scale of the outbreak. It also helped to respond with speed and decisiveness against a wider backdrop of indifference and indecision. And this is one of the biggest strengths of a trusted network of collaborators. It can empower you to take the drastic, necessary leaps that others aren't prepared to take. You can hear more from Dr. Charity Dean in her episode of Masters of Scale Rapid Response, which you can find in your podcast feed. In Stefan's case, his findings at Davos made him drop all his plans and fly to Washington.
14:59 Speaker 02 I buy one-way ticket from Zurich to DC, where I meet Dr. Fauci in the morning, go to FDA, we go to BARDA. We talk to DARPA, you know, part of the Department of Defense and so on. So to all our contacts, which was so priceless, who I built over many years before.
15:14 Speaker 03 Stefan took what he learned from those contacts in Washington DC back to his team in Boston.
15:20 Speaker 02 I spent a few days just trying to convince my team and my board that this is a 1918 pandemic happening and we need to change everything, how we organize, how we focus on this one. Because for the first few weeks before that, I had a few people on my team saying, dude, why are we wasting time on this Chinese virus? It's total destruction, we have 20 great drugs, it's going to be gone in a few months.
15:41 Speaker 03 The way Stefan got his team on board is not just important for biotech companies moving fast in a pandemic. It's one of the biggest challenges when leading a startup. You will frequently need to make a bet on how a situation is going to develop. And ideally, you need everyone on your team to buy in. This is why staying in sync with your team is so important. It makes it easier for everyone to get on the same page, and this greatly increases your odds of success. Stefan made his case, backed up with the information he'd collected from his network at Davos and in Washington, and convinced his team that this outbreak needed their undivided attention.
16:18 Speaker 02 And so I have to pivot the company, I have to think about how do I keep the pipeline working, because if I'm wrong, I'm going to lose a lot of time and resources. And then we have not enough money.
16:28 Speaker 03 Moderna's platform was tailor-made to respond quickly to a pathogen like coronavirus. As we heard earlier, the mRNA vaccine technology spearheaded by Moderna meant a vaccine could be designed in minutes rather than months. However, putting that vaccine into production so that it'll be ready to roll out if the Wuhan outbreak became a pandemic would be a huge upheaval and risk for the company.
16:52 Speaker 02 And then I'm like, but if it works, which I believe, then that's a piece that is really crazy about this technology because it's software-like, and we had to work on Corona before, and we had to work on nine vaccines before. So if you put all those things together, it's like, this is going to work.
17:05 Speaker 03 It was exactly the kind of problem that Stefan and Moderna thrived on. For Stefan, this culture is embodied in his friend and colleague, Stephen Hoag.
17:16 Speaker 02 Stephen Hoag, who is the president of a company, he runs R&D, has been my partner since we were 20 people and a dog in the early days. He's an amazing human being and an amazing scientist. And actually, he gets energy from things failing.
17:38 Speaker 03 Gaining energy from things failing is exactly the mindset you have to have coursing through your network of collaborators. And having someone like Steven Hoag at the center of your network is a good way to make this happen.
17:50 Speaker 02 When something doesn't work,
17:53 Speaker 02 he's so curious and so long-term driven and so obsessed about learning and has such a compounding mindset and long-term view on things.
18:04 Speaker 02 He gets in a room, totally cross-functional team. So you have engineers and talks people and biologists and doctors and chemists and sometimes physicists and at different levels, you know, we don't care about VPs and titles.
18:19 Speaker 02 Okay, just throw ideas now. There's no stupid idea. And he just takes notes and it could be 10 or 20 or 50, doesn't care. He just takes all the ideas until the room is sucked out of ideas.
18:32 Speaker 02 And then he starts challenging and pressure testing intellectually all the ideas to select those that are worth testing, to understand what will happen. I need to run 10 or 15 experiments.
18:45 Speaker 02 And once we know what happened, then we can go fix it.
18:51 Speaker 03 This is what all great teams trying for moonshots need to do. Don't just accept failure, embrace the failure, get excited by the failure. But here's the important thing to remember. Failure in itself is not something to aim for. Rather, aim for the learning that comes with failure. Because what you learn from failure is hard-won knowledge, knowledge that more failure-versed competitors will not have. That's why you want your team to be a resilient network of collaborators who use failure as a means to zoning in on success.
19:26 Speaker 02 And that's really the beauty of Moderna, this amazing excitement. When something doesn't work, you can feel the building vibrating of excitement and very positive tension. Every time we have scientific stumbles, we emerge way stronger.
19:42 Speaker 03 With the company now focused on its COVID-19 vaccine, Stefan was thinking ahead to just how to get the vaccine to people.
19:50 Speaker 02 We need to start to buy equipment now, and everybody is going to want syringes, and we need to buy them now in vials. And how do we get suppliers?
19:59 Speaker 03 Stefan had a ready network of suppliers, but none of them were prepared to join him all in on the dismal bet that COVID-19 was an existential threat. It's worth noting here that not all networks run on the currency of collaboration. Some run on the currency of mutual benefit. Some simply run on money, and that's fine. You can't expect every network to be made of altruistic collaborators driving toward the same mission. But that doesn't mean such networks are bad in any way. You just need to make sure you know the particular currency before you start collaborating.
20:34 Speaker 02 Because when you go to a supplier and you tell them, "I need 10,000 times more product from you." They look at you, "What are you talking about?" And so some suppliers, we had to pay them upfront the entire purchase of a raw material. Because they're like, "Look, guys, if your drug fails, and you guys have never launched one, by the way, I'll go under. Because I have to buy new machines. I have to hire more people. I have to buy my own raw material or chemicals or whatever to make your stuff. And if you guys don't take delivery and pay me, I'll go under."
21:01 Speaker 03 Now, Stefan had a new problem. And if he didn't find a solution, the Moderna vaccine wouldn't be able to reach anyone.
21:09 Speaker 03 We all know the disappointment that comes when a grand gesture falls flat. Something that seemed impressive in the moment but didn't deliver the results you expected. Marketing budgets too often fall into that trap, aiming for big impressions, big reach, but without the revenue to back it. LinkedIn has a name for it: Bullspend. LinkedIn Ads generate the highest ROAS of all major ad networks. They target by company, industry, job title, and more. Spend $250 on your first campaign on LinkedIn Ads and get a $250 credit for the next one. Just go to LinkedIn.com/scale. That's LinkedIn.com/scale. Terms and conditions apply.
21:52 Speaker 03 When you've built substantial wealth through your business, it's often tied up in a single equity position. The upside is real, but so is the risk, and knowing when to act isn't always obvious. Creative Planning works with business owners to build a strategy around concentrated equity, when to diversify, how to manage tax risk, and how to protect what you've spent years building. Creative Planning, where wealth works together. Learn more at creativeplanning.com/mastersofscale.
22:23 Speaker 00 Stripe Treasury is your new financial operating system built for what's next. With Stripe Treasury, the place your business accepts payments is also where you can store balances, move funds, and pay vendors worldwide. If you're building for global scale, get a business bank account that lets your money move instantly, whenever and wherever you need it. Learn more at stripe.com/treasury. Stripe is not a bank. Banking services provided by Fifth Third Bank, National Association Member, FDIC.
22:55 Speaker 03 We're back with Stephane Bancel, CEO of Moderna. And if you're a member, don't forget you can hear the full uncut version of this interview in the Masters of Scale app. To become a member, visit masterscale.com/membership. Even with the extra space of a two-part episode, we couldn't fit in all of Stephane's exciting story, like more details of his tour of Silicon Valley, his insights on how to onboard new staff at speed, and his full vision for the future of mRNA technology. It's all in the uncut interview, and you won't want to miss it. Before the break, we heard how Stephane had convinced his team they needed to pivot and prepare for a global pandemic. But they hit a wall with their suppliers, who needed to be paid upfront for the huge volumes of equipment Moderna would need to roll out the vaccine.
23:40 Speaker 02 We need machines, we need people, we need raw materials. We have four big things we needed. And I started to spend a lot of time trying to find money, because we need billions of dollars, and we don't even have one on the balance sheet. I'm like, we need three, four, five, six billion dollars to get this done.
23:54 Speaker 03 The stakes were far higher than simply a failed product launch.
23:59 Speaker 02 It would be so awful for the world if we have this vaccine working in December, and I cannot make any. That would be just a human tragedy, literally. And so I failed miserably in Q1 to raise a penny. Everybody said no.
24:12 Speaker 03 Fortunately, when it came to the cost of clinical trials, Moderna and other drug companies racing to make COVID vaccines like Johnson & Johnson and AstraZeneca recovered.
24:22 Speaker 02 So all the clinical trials were paid for by the US government, and the entire planet benefited because we use the same data in Europe, Japan, and so on. So everybody in the planet owes a lot to US taxpayers. We offered a discount of a billion dollars to the US government because we say, "Look, if we're going to make money out of this thing, we need to come even, obviously. We are super thankful for the help."
24:43 Speaker 03 Moderna still needed a huge injection of capital to be able to rapidly scale up its ability to manufacture the vaccine. So Stephan decided to raise the money from investors. It would be a time-consuming and complex process that would take him away from the important work of actually producing the vaccine. But then, a member of Stephan's network, James Gorman, CEO of Morgan Stanley, made him an offer.
25:07 Speaker 02 And he's like, "I do the world deal." I said, "What do you mean?" He's like, "I cannot have you waste time doing a roadshow. So I'll buy all the stock. I'll take the risk on Morgan Stanley balance sheet."
25:18 Speaker 03 Stephan's words should remind us that the battle against COVID has been a story of networks of collaborators joining together in a shared, essential mission. And this kind of collaboration reaches far beyond the race to create a vaccine. For some more examples, we turn to Corey Zarick, Executive Director at Beck Center for Social Impact and Innovation at Georgetown University. Early in the pandemic, Corey and her team were alarmed at the potential for government systems to be overwhelmed.
25:47 Speaker 06 In March 2020, a lot of us were watching the news unfold around us and having similar realizations all at once. Some of my former colleagues I worked with at the White House, we had all been there when the website healthcare.gov launched and wasn't ready for the demand that it received. And so we all had that flashpoint where we recognized that type of breakdown was about to occur to every government service on any topic at every level of government.
26:18 Speaker 03 Corey and her team put the call out through their networks.
26:21 Speaker 06 So within hours, hundreds of people had raised their hands to volunteer, and within days, there were a few thousand. And if you think back to that time, so many of us wanted to be useful.
26:30 Speaker 04 And we didn't know what to do. We had all these human centered designers and data scientists and software developers and found that they wanted to serve their communities as well.
26:40 Speaker 03 The open voluntary nature of the network also meant it could pivot to new challenges as they arose.
26:46 Speaker 04 Over time, the work shifted with the need and we had to learn how to vote in a pandemic for the first time or to deliver vaccines at scale, to institute and implement new assistance programs like the emergency rental assistance program.
27:02 Speaker 03 That loose, rapidly convened network of collaborators continues to this day, working under the auspices of the nonprofit U.S. Digital Response.
27:11 Speaker 04 Over the past two years, U.S. Digital Response has worked with more than 40 million people in nearly 40 states and territories in the United States, 200-plus governments on hundreds of projects, and has really proved itself a valuable resource and a partner as part of our civil society civic tech sector.
27:32 Speaker 03 For Corey, transparency is the key ingredient in building a network of collaborators that is agile, scalable, and trusted.
27:40 Speaker 04 It's key to be doing all of this work in the open. That's one of the critical pillars of how to approach a network from our perspective. Really want others to be able to come across and find what you've created and what you've built. Maybe they join your network. Maybe they simply learn from it and self-help. But by putting together resources in the open, writing your software in open source code, by publishing toolkits and playbooks and other replicable models and resources, your network can only grow and grow.
28:10 Speaker 03 Openness compounds the rate your network of collaborators scales, and Corey is an expert at leveraging this. Similarly, Stephane had spent a decade creating his global network of scientists, government officials, and business leaders. It had helped him get up-to-date information on the pandemic and get the funding he needed to deliver the vaccine. Meanwhile, there were promising results from the clinical trials.
28:36 Speaker 02 So I got the first sense when in May, we got the phase one data because everybody in the study, and he was small, but he was everybody, made antibodies way above the level that people had been naturally infected. So it was a very good sign. Nobody knew how much you really needed, but above was a good sign. And it was way above. And it was also true in older people, which of course was super important because of casualties, death and hospitalization we were seeing in that spring. And so at that time, I knew it was going to work. I just didn't know how well it was going to work. This thing is going to work.
29:09 Speaker 03 However, there was something lacking in the test, to be precise, in the test subjects.
29:14 Speaker 02 We slowed down by two weeks and we ended up being number two at the finish line. And we had less, two weeks where we had the vaccine to protect anybody. We said, look, if this is a vaccine that only, you know, white people take because, you know, African American or Hispanic background or Asian do not have enough data that their healthcare professional that they trust and so on, say, yeah, you can take it. It's safe. It's working in Asian. It's working African American. We said, look, we would have failed. This is a vaccine for humanity. It's a vaccine for the planet. It's not a vaccine for white people. It has never our intent, as you can imagine. And so it was important.
29:50 Speaker 03 A moonshot without everyone on board couldn't be counted as a complete victory. Stephane's optimism was vindicated.
29:58 Speaker 02 And then it was in November, the day before, we of course, we announced the data publicly was on a Sunday. We have an independent safety monitoring board met and reviewed the blinded data with placebo and so on. I was not at that meeting, but were informed after of a 94% efficacy and so on, which was crazy. And we spent two minutes with my team, just with my team, once we disconnected the other members, just to think, okay, what do we do and so on. And then I was at home, it was on a Sunday, and I called my wife and my girls, and I just started crying. And we had a big kind of family hug, everybody crying like little kids, you know, just, I was just so happy because what went through my head emotionally and so on was, yeah, we were going to be able to help a lot of people.
30:38 Speaker 03 Yep. No, and clearly. And then what was getting your own first dose like?
30:43 Speaker 02 So it was surreal because in the 10 years before, I never thought, and I hope I will never need another product because we are working on cancer drug and drug for people with heart attacks and rare genetic disease, all very bad stuff. And what was very special is I went with my wife and the nurse were very nice because the nurse were vaccinated before us. And so we were super thankful when they realized now I was the CEO and so on, and I started the company and everything. And so I said, do you mind if I got the shot at the same time as my wife? They moved the partition and so on to put the two chairs together and we're talking to each other. I took my wife's hand and we both literally on respective arms got our shot. And it was a super special moment because the only thing I will go through my mind
31:25 Speaker 02 and my heart at the time was, I was just thinking about all our friends, all our employees, and using that as my mental model to think about people on the planet, to say there are going to be so many people that are going to like this, get the shot in their arm and going to be able to feel safe and be able to hug loved ones again and go outside and go to restaurants and have a human life again. And that was super special to be able to do it with my wife, who had been an amazing support and partner through this crazy entrepreneurial journey. So that was a super special moment.
31:57 Speaker 03 It was a vindication of the platform that Moderna had been building for a decade and a clear sign that it would be the platform for many more amazing achievements and the potential for growing a huge network of collaborators. So now you have a platform, obviously COVID and variants is one kind of applications and variations of it. What does that platform now mean for how you're looking forward at Moderna?
32:22 Speaker 02 So how long do you have? So at a very high level, there are at least four things that we're going to change forever in a very profound way. And it's going to take us, you know, a bit of time, some things will happen in months, something will happen in a couple of years, something might take 10 years.
32:38 Speaker 03 Stefan did indeed go into fascinating detail about each of these and Master Scale members can hear it all in the uncut version of this interview, but we'll briefly touch upon each before we finish. The first is respiratory disease.
32:52 Speaker 02 But basically, the first big thing that this is going to change forever is we are developing an annual booster against all respiratory viruses in one shot. And so our vision is to package in one single dose that you can get at your local CVS or pediatrician or favorite doctor. Our goal is we should have on this planet, nobody will get sick, hospitalized or die from a respiratory virus. It's going to take us five, seven, 10 years to get to my vision. It is a solvable problem.
33:21 Speaker 03 The second goal is to tackle latent viruses.
33:25 Speaker 02 Those are viruses that basically, once in your body, never leave your body. So you know a few, you know HIV, you know hepatitis B and C, you know HPV that drive cervical cancer. Once in your body, they are like a drug, like you know, a heavy backpack if you run the marathon on your immune system.
33:44 Speaker 03 The third goal is combating chronic conditions.
33:48 Speaker 02 We are working on oncology treatment, on rare disease treatment, on cardio autoimmune treatment. And so there's a lot of treatments we think we can develop, where you'll have to get a drug maybe every two weeks, every four weeks, maybe for a few more, maybe for a lifetime if it's a rare genetic drug where you're missing the instruction in your DNA.
34:07 Speaker 03 And the fourth goal is to vastly improve gene editing techniques.
34:12 Speaker 02 So we think there's a lot of ways to improve gene editing technology, to basically go and cut your DNA inside your body, to put a better piece of DNA to make you healthier or to cure disease or whatever. That will take a bit longer, but it might have a much more profound impact on life.
34:29 Speaker 03 Each of these admirable goals have the potential for transforming our world and saving countless lives. And Stefan is convinced the moonshot platform he helped build at Moderna is a strong enough foundation for doing this. Combined with an active, transparent collaboration across a network encompassing science, government, business, and society, keeping this network open, diverse, and thriving will open the door to many future moonshots. I'm Reid Hoffman. Thank you for listening.
35:03 Speaker 00 Global hiring is such a headache when you're building fast, but don't let payroll, compliance, or onboarding slow you down. Companies like 11 Labs and Mistral are scaling globally and effortlessly with Deal. 11 Labs quadrupled their headcount in 2025, and Mistral pays 364 employees across 15 countries, all from one system. Build your global team with Deal. Visit deal.com/mos and start expanding your business today. That's D E E L dot com slash M O S.
35:40 Speaker 00 Before we get to the rest of our conversation today, I want to spend a moment sharing with you about Masters of Scale Summit, which returns to San Francisco this October 20th to 22nd. So many of us feel overwhelmed right now. It feels like so much of the world is careening, and we don't have power, we don't have agency. That's the thing about the Masters of Scale Summit. It's really designed to remind us that we do have agency, agency to lead, agency to design, to build the relationships and the partnerships that empower us and to make the change that we want to see. We program a stage, we curate an audience, we set a schedule that builds in time for these relationships to be made and to grow so that by the time you leave Summit,
36:24 Speaker 00 you are fired out of a cannon, ready to run through walls to do better in the world with the agency that you actually have. I hope to see you there. Visit mastersofscale.com/summit.
36:43 Speaker 00 Every business hits the same wall the moment your business outgrows the systems that got you here. Spreadsheets everywhere, five different logins, data scattered across entities that don't even talk to each other. If your finance team spends more time finding data than using it, that's when you need the Intuit ERP. Intuit Enterprise Suite is the AI-native ERP solution that's powerful, painless, and proven, built for businesses scaling fast without the complexity that usually comes with it. From the makers of QuickBooks, learn more at intuit.com/ERP.
37:23 Speaker 03 Masters of Scale is a Wait What original. Our executive producers are June Cohen, Darren Triff, and Jordan Cloud. Our head of content and production is Lori Hoffman. Our producers are Adam Skuse, Katherine Clark Gray, Marie McCoy Thompson, Alex Morris, Tucker Legursky, and Holly Bondi. Our editor at large is Bob Safian. Our music director is Ryan Holiday. Original music and sound design by Eduardo Rivera. Audio editing by Keith J. Nelson, Stephen Davies, Andrew Nalt, and Mike Gallagher. Mixing and mastering by Brian Pugh. Special thanks to Chris Ye, Alisa Schreiber, Arya Finger, Sayadis Sapieva, Greg Beato, Adam Heiner, Colin Howarth, Willem Crowells, Tim Cronin, Kelsey Capitano, Sammy Aputa,
38:06 Speaker 03 Anna Pizzano, Sarah Tarter, Leir Sermentis, Charlie Meneses, Chinime Ezequena, Emily McManus, and Mina Kurusawa. Become a member of Masters of Scale to get access to a year's worth of courses and content on the Masters of Scale courses app. Find out more at masterscale.com/membership.
38:29 Speaker 00 Humans will never be more intelligent than AI. There's going to be two types of companies. Those are great at AI and those that went out of business because they weren't.
38:38 Speaker 01 How do we build a future that is human-centered?
38:43 Speaker 07 I'm Rana Elkhayubi, and on my podcast, Pioneers of AI, we answer that question and so many more. As an AI scientist, entrepreneur, and investor, I know what it takes to build AI that works for everyone. Every week, I sit down with the pioneers shaping our future, and we take you behind the scenes of the AI that's transforming our lives. Find Pioneers of AI wherever you tune in.
Previous Rapid Response: A global benefit concert for Ukraine, w/World Unite for Ukraine’s Victoria Yampolsky Next Rapid Response: Why business must be a force for good, w/former American Express CEO Ken Chenault Page updated October 26, 2026 · transcript and summary are machine-generated